Announced details
Curative treatment of dystrophic epidermolysis bullosa
The Company has pursued research and development of “regeneration-inducing drugs” with Osaka University. The patent applicant is National University Corporation Osaka University
National university corporation. Other locations, representative, business activities, paid-in capital and year established are Not disclosed
US patent grant number: 12751974; application number: 17/423,285. Registration date and expiration date are Not disclosed
There will be no impact on full-year results for the fiscal year ending July 2027. If any matter requiring disclosure arises, it will be disclosed promptly
The company does not address Contract Value / Offering price.
Support from the Japan Agency for Medical Research and Development (AMED). 6 December 2024: “Notice of Selection for AMED's FY2024 Open Call Project for Promoting the Industrialization of Regenerative, Cellular and Gene Therapies”
| Item | Details |
|---|---|
| Names of Products / Services Covered | Stem cell gene therapy technology (Development Code: SR-GT1) |
| Counterparty | Osaka University National University Corporation |
| Counterparty overview | National university corporation. Other locations, representative, business activities, paid-in capital and year established are Not disclosed |
| Relationship with the Company | The Company has pursued research and development of “regeneration-inducing drugs” with Osaka University. The patent applicant is National University Corporation Osaka University |
| Applicable area | Curative treatment of dystrophic epidermolysis bullosa |
| Registration number and expiry date | US patent grant number: 12751974; application number: 17/423,285. Registration date and expiration date are Not disclosed |
| Impact on Business Performance | There will be no impact on full-year results for the fiscal year ending July 2027. If any matter requiring disclosure arises, it will be disclosed promptly |
| Source | Support from the Japan Agency for Medical Research and Development (AMED). 6 December 2024: “Notice of Selection for AMED's FY2024 Open Call Project for Promoting the Industrialization of Regenerative, Cellular and Gene Therapies” |
Items this document does not state (10)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To develop curative treatments for inherited rare diseases, building on the research and development of “regeneration-inducing drugs” that the Company has pursued with Osaka University.